AEON Biopharma
AEON
47 hedge funds and large institutions have $126M invested in AEON Biopharma in 2021 Q2 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
42.19% more ownership
Funds ownership: 0% → 42.19% (+42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
+$12.1M |
| 2 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$8.41M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$7.68M |
| 4 |
LA
Linden Advisors
New York
|
+$5.83M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$5.83M |
Top Sellers
AEON Hedge Fund Activity: Q2 2021 in Review
47 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2021, worth a combined $126M.
Buyers outnumbered sellers: 47 funds opened new AEON positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Davidson Kempner Capital Management, opening a new position worth an estimated $12.1M.
- 47 institutional investors held AEON Biopharma (AEON) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $126M of AEON Biopharma stock for Q2 2021.
- 47 funds opened new AEON Biopharma positions in Q2 2021 and 0 closed out, a net change of +47 holders.
- The largest AEON Biopharma buyer in Q2 2021 was Davidson Kempner Capital Management, an estimated $12.1M added.
Based on aggregated 13F filings for Q2 2021.